Health minister affirms Qatar's active role in supporting global health security
GENEVA: Minister of Public Health HE Mansour bin Ibrahim Al Mahmoud has affirmed the State of Qatar's firm commitment to supporting the World Health Organization (WHO) and its mission to build a healthy future based on strong partnerships and a clear vision for achieving the values of justice.
He emphasized Qatar's belief that health is both an end and a means to achieving a more just, secure, and humane world.
In his address to the World Health Assembly currently being held in Geneva, the Minister said that the State of Qatar has a firm belief that health was a cross-border issue. He added that the country was committed, through the high-level strategic dialogue with the World Health Organization (WHO) and the 14th General Programme of Work, to achieve WHO's strategic objectives.
He highlighted Qatar's active role in supporting global health security and promoting development and humanitarian assistance to affected countries.
This was demonstrated by its rapid response to crises and ensuring equitable access to health resources in cooperation with its regional and international partners.
The Minister also noted that the Third National Health Strategy, in line with Qatar National Vision 2030, focuses on achieving universal health coverage, health equity, improving patient experience, and enhancing the efficiency of the health system.
He indicated that the ongoing humanitarian tragedy in the Gaza Strip, which has been ongoing for more than a year and a half due to the Israeli aggression, calls for intensified efforts by the international community and international organizations to end this suffering and restore the human right to a dignified life and healthcare.
It is worth noting that the World Health Assembly is being held in Geneva, Switzerland, from May 19 to 27 under the theme 'One World for Health'.
Al Mahmoud is heading the State of Qatar's delegation participating in the meetings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
2 hours ago
- Qatar Tribune
Sheikha Moza opens HSCT ward at Sidra Medicine
Tribune News Network Doha HH Sheikha Moza bint Nasser, Chairperson of Qatar Foundation for Education, Science and Community Development, officially inaugurated the new paediatric Hematopoietic Stem Cell Transplant (HSCT) ward at Sidra Medicine, a Qatar Foundation entity. The new ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions. During the visit, Sheikha Mozatoured the facility, engaged with clinical teams, and received an overview of the HSCT programme's role in advancing care and stem cell and gene therapies for children in Qatar and the region. Sheikha Moza was accompanied by Minister of Public Health HE Mansoor bin Ebrahim bin Saad Al Mahmoud, members of Sidra Medicine's Board of Directors and senior leadership, including Dr Iyabo Tinubu-Karch, Chief Executive Officer and Prof Ibrahim Janahi, Chief Medical Officer. The HSCT ward is a core part of Sidra Medicine's HSCT Programme, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic). Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new pediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections - one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
Qatar Tribune
2 hours ago
- Qatar Tribune
‘New paediatric Hematopoietic Stem Cell Transplant Ward expands access to life-saving care for children'
Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, said: 'The opening of our new paediatric Hematopoietic Stem Cell Transplant Ward, the first of its kind in the country, marks a major step in expanding access to life-saving care for children in Qatar and the region. As the HSCT program grows, it will play a vital role in reducing the need for outbound referrals and in positioning Qatar as a center of excellence for pediatric cell and gene therapies. This is about building sustainable, high-quality care close to home for our patients and their families.' Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine, said: 'The launch of the HSCT Ward reflects our commitment to supporting the Qatar National Vision 2030. It strengthens the foundation of a knowledge-based economy by building national expertise in precision and regenerative medicine. Our goal is to ensure that every child in Qatar can access the best possible treatment, close to home and grounded in clinical excellence.' Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections—one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care. With an initial capacity of 20 beds, the new pediatric HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage. Dr Ayman Saleh, Division Chief of Pediatric Hematology-Oncology & Hematopoietic Stem Cell Transplant at Sidra Medicine, said: 'Our HSCT program brings together key specialties to deliver advanced and curative care for children with complex conditions. With four autologous procedures successfully completed and plans underway to offer allogeneic transplants in the near future, we are building a strong foundation for pediatric cellular therapy in Qatar. This service is a testament to the pioneering and family-centered care and cure approach that we offer to all our patients.' In addition to treating patients with various blood diseases and cancers, the HSCT program at Sidra Medicine is the core part of its precision medicine strategy to facilitate genomic research programs for pediatric autoimmune disorders, genetic and rare diseases. Sidra Medicine's HSCT program is further enhanced by a Good Manufacturing Practice (GMP)-qualified laboratory team operating under the Advanced Cell Therapy Core (ACTC). The ACTC manages the processing and cryopreservation of hematopoietic stem cells and is currently working toward Sidra Medicine's qualification as a treatment center for Casgevy, a gene therapy for thalassemia and sickle cell disease. Dr Chiara Cugno, Director of the Advanced Cell Therapy Core and GMP Facility at Sidra Medicine said: 'Our GMP-qualified laboratory is a key enabler in delivering safe and effective cellular therapies. By maintaining the highest standards in cell processing and cryopreservation, we are supporting precision treatments for children with cancer, blood, and immunologic disorders. It is an essential part of ensuring every child receives the most personalized care possible.' All HSCT program services will be open to both local and international patients, with more than 50 children currently awaiting transplantation in Qatar. Future phases for the HSCT program include scaling allogeneic transplant capacity and introducing CAR-T cell and gene therapies. The HSCT program includes a multidisciplinary team of specialized physicians, apheresis-trained staff, dedicated HSCT nurses, and allied health professionals. The Sidra Medicine care team also involves experts in immunology, infectious diseases, radiology, psychology, pharmacy, nutrition, child life, and social work. The integrated approach ensures comprehensive and patient-centered care throughout the transplant journey. Before a transplant, every child will go through a detailed evaluation at Sidra Medicine's outpatient clinic to ensure they are ready for the procedure. Once admitted, the children will undergo conditioning chemotherapy to prepare their bodies for the stem cell infusion. They will then be monitored very closely during the aplasia phase, when their immune system is at its weakest. Most patients will stay at the hospital for about 30 to 40 days. Following discharge, they will continue their care through regular follow-ups in an outpatient setting. In addition to medical and nursing care, Sidra Medicine offers support services for patients and families, including social work, clinical nurse specialists, and case management. While formal support groups are under development, ongoing engagement with families is embedded throughout the care process.
Qatar Tribune
2 hours ago
- Qatar Tribune
Israeli attacks kill 27 aid seekers in Gaza, says health ministry
Agencies Gaza Israeli forces have killed at least 27 Palestinians and injured 90 more as they opened fire close to an aid distribution site in Rafah, according to the Ministry of Health in Gaza. The latest killings came early on Tuesday at the Flag Roundabout, near an aid hub operated by the Gaza Humanitarian Foundation (GHF). It was the third such incident around the Rafah hub in as many days. Gaza's authorities report that more than 100 aid seekers have been killed since the United States- and Israel-backed GHF started operating in the enclave on May 27, with reports of violence, looting and chaos rife. The Israeli military said it had fired shots as 'a number of suspects' deviated from the regulated routes, on which a crowd was making its way to the GHF distribution complex. The 'suspects' were about 500 metres (approximately 550 yards) from the site, the military said in a statement on Telegram, adding that it was looking into reports of casualties. The death toll was confirmed by Zaher al-Waheidi, head of the Gaza Health Ministry's records department. A spokesperson for the International Committee of the Red Cross, Hisham Mhanna, said 184 wounded people had been taken to its field hospital in Rafah, 19 of whom were found dead on arrival, and eight others died later of their wounds. Video verified by Al Jazeera's Sanad fact-checking agency showed the arrival of dozens of injured people at the hospital. Gaza's Government Media Office accused Israel of 'a horrific, intentionally repeated crime', saying it has been luring starving Palestinians to the GHF centres – controversially opened following an 11-week total blockade to take over most aid distribution from the United Nations and other aid agencies – and then opening fire. It said Tuesday's death toll brought the number of aid seekers killed at aid sites in the Rafah governorate and the so-called Netzarim Corridor since GHF launched operations to 102, with 490 others injured. The United Nations on Monday demanded an independent investigation into the repeated mass shootings of aid seekers in Gaza. 'It is unacceptable that Palestinians are risking their lives for food,' said Secretary General Antonio Guterres. 'I call for an immediate and independent investigation into these events and for perpetrators to be held accountable.' 'We heard from witnesses that there was chaos,' said Al Jazeera's Hind Khoudary, reporting about Tuesday's killings from Deir el-Balah in central Gaza. 'The Israeli forces just opened fire randomly, shooting Palestinians … using quadcopters and live ammunition.' Health Ministry officials and doctors said most of the wounded have been hit in their chest and head, she added. The bloodshed, she continued, had unfolded in the same way as on the previous two days, amid ongoing chaos around the aid distribution centres. 'There's no process. There's no system,' she said. 'You just need to run first to be able to get the food.' Rasha al-Nahal told The Associated Press news agency that 'there was gunfire from all directions', and that she saw more than a dozen people dead and several wounded on the road. When she finally made it to the distribution hub, there was no aid, al-Nahal said, adding that Israeli troops 'fired at us as we were returning'. Another witness, Neima al-Aaraj, from Khan Younis, described the shooting as 'indiscriminate'. 'I won't return,' she said. 'Either way, we will die.' The Israeli military, in its statement on Telegram, said troops had fired warning shots as people deviated from 'designated access routes' and 'after the suspects failed to retreat, additional shots were directed near a few individual suspects who advanced toward the troops'. However, it denied firing on civilians or blocking them from accessing aid. This account echoes statements around similar incidents on Sunday, when 31 aid seekers were reportedly killed, and on Monday, when three more were killed.
